Clinical Trials
2 trialsNCT02109653 2020-11-13
Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
Array BioPharma
Phase 2 Withdrawn
NCT02263898 2020-07-27
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn